Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EyeCyte Inc.

Latest From EyeCyte Inc.

Biotechs Eye Macular Degeneration

Spurred by the commercial success of Lucentis, start-ups developing new therapeutics for AMD tap into a growing understanding of the pathogenesis of the disease. In this issue, we profile five emerging AMD drug developers: Acucela, Iconic Therapeutics, MacuCLEAR, Ophthotech, Optherion and Sirion Therapeutics.

New Stem Cell Therapies

Recent research advances and relaxation of government restrictions have opened the stem cell field to product possibilities. Companies developing these potentially revolutionary products must also come up with workable business models. In this issue we profile five emerging contenders: Amorcyte, California Stem Cell, Cardio3 BioSciences, CellDesign and Fate Therapeutics.
BioPharmaceutical Strategy

Private investment round-up: June 2008

Investments in emerging pharmaceutical and biotech companies continued to decline in June, with around 10 companies raising just $214.5 million in private fundraising, just over half of what was raised in April. Significantly, confidence in the US market has fallen dramatically with only seven companies representing the US in Scrip’s study. In April, it had appeared that US investors were able to shrug off the subprime fiasco and weather the current financial storm, but it now appears that confidence has again waned. Indeed, unlike April, in which US companies accounted for 99% of all private fundraising conducted, in June this figure fell to 70%.

Dermatology Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • EyeCyte Inc.
  • Senior Management
  • Mohammad A El-Kalay, PhD, Pres. & CEO
  • Contact Info
  • EyeCyte Inc.
    La Jolla, CA
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register